Startups are promoting embryo screening for traits ranging from genetic disease risk to intelligence, raising fresh questions about science, ethics, and consumer protection.
The services target people using in vitro fertilization, or IVF. Their claims suggest parents could compare embryos using genetic estimates before deciding which one to implant. Critics warn that disease testing and predictions about complex traits are not equally reliable.
Disease Tests Differ From Trait Predictions
Embryo testing is already used in fertility care. Established tests can identify chromosome problems or specific gene variants linked to inherited disorders. These tests may help families with a known medical risk.
Newer services seek to predict conditions influenced by many genetic variants. Some also promote estimates for nonmedical traits. Startups claim screening could cover “everything from genetic diseases to IQ.”
That broad promise can blur major scientific differences. A harmful variant in one gene may have a strong, well-studied link to disease. Intelligence, heart disease, diabetes, and many psychiatric conditions involve numerous genes, environmental factors, and chance.
For complex outcomes, companies may use polygenic scores. These scores combine information from many genetic variants into a statistical estimate. They do not provide a diagnosis or guarantee that a trait will develop.
Limited Choices Inside an IVF Cycle
Polygenic scores are often studied across large groups. Using them to compare a small number of related embryos presents a different challenge.
Siblings receive different mixes of DNA from the same parents, but their genetic differences are limited. An IVF cycle may also produce only a few embryos suitable for testing. That can narrow the expected benefit of ranking them.
Several factors can shape the accuracy and value of any prediction:
- The size and diversity of the genetic database used to build the score.
- The number of embryos available for comparison.
- The strength of the link between the score and the predicted outcome.
- Environmental influences during childhood and adulthood.
Genetic estimates may also perform unevenly across ancestry groups. Many genetic research databases have included more participants of European ancestry than other populations. A score trained on one population may be less accurate for another.
Marketing Claims Meet Ethical Concerns
Supporters of expanded screening argue that parents already make difficult reproductive decisions. They say more genetic information could help families reduce serious health risks, provided the limits are explained clearly.
Skeptics question whether consumers can give informed consent when predictions are uncertain. Advertising may present small shifts in statistical probability as meaningful control over a future child’s life.
Screening for IQ creates added concern because intelligence is difficult to define and measure. Education, health, family resources, and social conditions all affect cognitive outcomes. A genetic score cannot capture those influences.
The practice could also increase social pressure on parents to select embryos according to disputed ideas about health, ability, or desirability. Access is another issue. IVF and added genetic testing can be expensive, placing these services outside many families’ reach.
Regulation and Evidence Will Shape Adoption
The central policy question is whether companies should be allowed to market complex embryo predictions before independent evidence shows a clear clinical benefit. Regulators, fertility clinics, and medical groups may need to distinguish disease prevention from elective trait selection.
Useful oversight could require companies to disclose error rates, ancestry limits, expected differences among siblings, and the evidence behind each advertised outcome. Independent counseling could help patients understand that embryo ranking changes probabilities rather than determining a child’s future.
Embryo screening may offer valuable information when it targets a well-understood inherited disorder. Claims about IQ and other complex traits rest on far less certain ground. The next stage of debate will focus on proof, transparent marketing, and the line between medical care and genetic preference.
